home / stock / cvac / cvac articles
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit ov...
CureVac N.V. (NASDAQ:CVAC) released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate. The ...
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday. The company announced interim data from the ongoing Phase 2 study assessing m...
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) ...
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell ...
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CV...
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing...
News, Short Squeeze, Breakout and More Instantly...
CureVac N.V. Company Name:
CVAC Stock Symbol:
NASDAQ Market:
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit ov...
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary s...
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMA...